Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in Tanzania

Vaccine

Volumn 28, Issue 48, 2010, Pages 7652-7658

  Lahey, Timothy ^a   Arbeit, Robert D ^b   Bakari, Muhammad ^c   Horsburgh, C Robert ^d   Matee, Mecky ^c   Waddell, Richard ^a   Mtei, Lillian ^c   Vuola, Jenni M ^e   Pallangyo, Kisali ^c   von Reyn, C Fordham ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Cell proliferation; HIV; Interferons; Tuberculosis; Vaccines

Indexed keywords

GAMMA INTERFERON; ISONIAZID; LIPOARABINOMANNAN; MYCOBACTERIUM VACCINE; PLACEBO;

ADULT; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM VACCAE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANZANIA; TUBERCULOSIS; VIRUS LOAD; WHOLE CELL;

ADULT; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; ANTITUBERCULAR AGENTS; BCG VACCINE; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; ISONIAZID; LIPOPOLYSACCHARIDES; MALE; TANZANIA; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS VACCINES; VIRAL LOAD;

EID: 78249245421     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.041     Document Type: Article

References (49)

1. Aronson J.D. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 1948, 58:255-281.
2. Ferguson R.G., Simes A.B. BCG vaccination of infant Indians in Saskatchewan. Tubercle 1949, 30:5-11.
3. Rosenthal S.R., Loewinsohn E., Graham M.L., Liveright D., Thorne M.G., Johnson V. BCG vaccination in tuberculous households. Am Rev Respir Dis 1960, 84:690-704.
4. Rosenthal S.R., Loewinsohn E., Graham M.L., Liveright D., Thorne M.G., Johnson V., et al. BCG vaccination against tuberculosis in Chicago: a twenty year study statistically analyzed. Pediatrics 1961, 28:622-641.
5. Levine M.I., Sackett M.F. Results of BCG immunization in New York City. Am Rev Tuberc 1948, 53:517-532.
6. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
7. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994, 271:698-702.
8. Sterne J.A., Rodrigues L.C., Guedes I.N. Does the efficacy of BCG decline with time since vaccination?. Int J Tuberc Lung Dis 1998, 2(March (3)):200-207.
9. Packe G.E., Innes J.A. Duration of protection against tuberculosis conferred by BCG vaccination in infancy. Arch Dis Child 1989, 64(April (4)):634-635.
10. Aronson N.E., Santosham M., Comstock G.W., Howard R.S., Moulton L.H., Rhoades E.R., et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. Jama 2004, 291(May 5 (17)):2086-2091.
11. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996, 348:17-24. Karonga Trial Prevention Group.
12. Skeiky Y.A., Sadoff J.C. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006, 4(June (6)):469-476.
13. Hoft D.F. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008, 372(July 12 (9633)):164-175.
14. von Reyn C.F., Vuola J.M. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002, 35(August 15 (4)):465-474.
15. Seng R., Gustafson P., Gomes V.F., Vieira C.S., Rabna P., Larsen O., et al. Community study of the relative impact of HIV-1 and HIV-2 on intrathoracic tuberculosis. Aids 2002, 16(May 3 (7)):1059-1066.
16. WHO Global Tuberculosis Control: Surveillance, Planning, Financing 2008, World Health Organization, Geneva.
17. Dye C. Global epidemiology of tuberculosis. Lancet 2006, 367(March 18 (9514)):938-940.
18. Havlir D.V., Barnes P.F. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999, 340(February 4 (5)):367-373.
19. Waddell R.D., Chintu C., Lein A.D., Zumla A., Karagas M.R., Baboo K.S., et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000, 30((June) Suppl. 3):S309-S315.
20. Vuola J.M., Ristola M.A., Cole B., Jarviluoma A., Tvaroha S., Ronkko T., et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. Aids 2003, 17(November 7 (16)):2351-2355.
21. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed. HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. Aids 2010, 13(January 28 (24(5))):675-685.
22. Nigou J., Gilleron M., Puzo G. Lipoarabinomannans: from structure to biosynthesis. Biochimie 2003, 85(January-February (1-2)):153-166.
23. Lahey T., Matee M., Mtei L., Bakari M., Pallangyo K., von Reyn C.F. Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis 2009, 9:21.
24. Iorio A.M., Alatri A., Francisci D., Preziosi R., Neri M., Donatelli I., et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine 1997, 15(January (1)):97-102.
25. Fonseca M.O., Pang L.W., de Paula Cavalheiro N., Barone A.A., Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23(April 22 (22)):2902-2908.
26. Mansoor N., Scriba T.J., de Kock M., Tameris M., Abel B., Keyser A., et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009, 199(April 1 (7)):982-990.
27. Brenchley J.M., Hill B.J., Ambrozak D.R., Price D.A., Guenaga F.J., Casazza J.P., et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004, 78(February (3)):1160-1168.
28. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417(May 2 (6884)):95-98.
29. Geldmacher C., Schuetz A., Ngwenyama N., Casazza J.P., Sanga E., Saathoff E., et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 2008, 198(December 1 (11)):1590-1598.
30. Lahey T., Sheth S., Matee M., Arbeit R., Horsburgh C.R., Mtei L., et al. Interferon γ responses to mycobacterial antigens protect against subsequent HIV-associated tuberculosis. J Infect Dis 2010, 202(8):1265-1272.
31. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24(5):675-685.
32. Lalvani A. Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment?. Clin Infect Dis 2004, 38(March 1 (5)):757-759.
33. Carrara S., Vincenti D., Petrosillo N., Amicosante M., Girardi E., Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004, 38(March 1 (5)):754-756.
34. Hanekom W.A., Dockrell H.M., Ottenhoff T.H., Doherty T.M., Fletcher H., McShane H., et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 2008, 5(July 1 (7)):e145.
35. Beveridge N.E., Fletcher H.A., Hughes J., Pathan A.A., Scriba T.J., Minassian A., et al. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb) 2008, 88(November (6)):631-640.
36. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am J Respir Crit Care Med 2010 Jun 17. [Epub ahead of print].
37. Abou-Zeid C., Gares M.P., Inwald J., Janssen R., Zhang Y., Young D.B., et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect Immun 1997, 65(May (5)):1856-1862.
38. Wang C.C., Rook G.A. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998, 93(March (3)):307-313.
39. Grembiale R.D., Camporota L., Naty S., Tranfa C.M., Djukanovic R., Marsico S.A. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000, 162(December (6)):2048-2052.
40. Hernandez-Pando R., Pavon L., Arriaga K., Orozco H., Madrid-Marina V., Rook G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 1997, 65(August (8)):3317-3327.
41. Janssen R., Kruisselbrink A., Hoogteijling L., Lamb J.R., Young D.B., Thole J.E. Analysis of recombinant mycobacteria as T helper type 1 vaccines in an allergy challenge model. Immunology 2001, 102(April (4)):441-449.
42. Camporota L., Corkhill A., Long H., Lordan J., Stanciu L., Tuckwell N., et al. The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 2003, 21(February (2)):287-293.
43. Hoft D.F., Blazevic A., Abate G., Hanekom W.A., Kaplan G., Soler J.H., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 2008, 198(November 15 (10)):1491-1501.
44. Cheon S.H., Kampmann B., Hise A.G., Phillips M., Song H.Y., Landen K., et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 2002, 9(July (4)):901-907.
45. Wallis R.S., Pai M., Menzies D., Doherty T.M., Walzl G., Perkins M.D., et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010, 375(9729):1920-1937.
46. Edwards L.B., Palmer C.E. Identification of the tuberculous-infected by skin tests. Ann NY Acad Sci 1968, 154:140-148.
47. Fine P.E.M. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346:1339-1345.
48. Edwards M.L., Goodrich J.M., Muller D., Pollack A., Ziegler J.E., Smith D.W. Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guerin. J Infect Dis 1982, 145:733-741.
49. Demangel C., Garnier T., Rosenkrands I., Cole S.T. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 2005, 73(April (4)):2190-2196.